Laferomax 3,000,000 IU, 10 suppositories — Made in Ukraine — Free Delivery

Pharmacological properties.

Pharmacodynamics.

Interferon alpha-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulatory effect. The active ingredient of the preparation Laferomax - interferon alfa-2b recombinant has an immunomodulatory effect on T- and B-lymphocytes, normalizes the content of immunoglobulin E, has antiviral activity. Antibodies that neutralize the antiviral activity of recombinant interferon alpha-2b are not formed, even when it has been used for 2 years, the functioning of the endogenous system is normalized.

Pharmacokinetics.

The pharmacokinetic properties of the preparation have not been studied.

Clinical characteristics.

Indications.

For adults:

• with papillomavirus infections (vulgar warts, genital warts);
• with urogenital mixed infections that are sexually transmitted;
• with precancerous diseases of the cervix.

Structure:

Active ingredient: interferon alfa-2b

1 suppository contains: recombinant human interferon alpha-2b - 1,000,000 IU or 3,000,000 IU;

excipients: tocopherol acetate 5% oily solution, ascorbic acid, solid fat.

Dosage form.

Suppositories.

Basic physical and chemical properties: suppositories, bullet-shaped, yellowish-white, uniform consistency.

Contraindications

Hypersensitivity to the components of the preparation; the patient has thyroid dysfunction; the presence of severe visceral disorders in patients with kaposi's sarcoma; severe cardiovascular disease; psoriasis; severe liver and / or kidney dysfunction; epilepsy and other diseases of the central nervous system (including functional); chronic hepatitis against the background of progressive or decompensated cirrhosis of the liver; chronic hepatitis in patients receiving or recently receiving immunosuppressive therapy (except for a short course of corticosteroid therapy); a history of autoimmune hepatitis or other autoimmune diseases. oppression of the myeloid germ of hematopoiesis.

Interaction with other medicinal products and other types of interactions.

With caution, the preparation should be used simultaneously with opioid preparations, analgesics, hypnotics and sedatives (potentially having a myelosuppressive effect).

With simultaneous use with preparations that are metabolized by oxidation (including with xanthine derivatives - aminophylline and theophylline), one should take into account the possibility of Laferomax's influence on oxidative metabolic processes. The concentration of theophylline in the blood serum must be monitored and, if necessary, the dosage regimen must be adjusted.

When using the preparation in combination with chemotherapeutic preparations (cytarabine, doxorubicin, teniposide, cyclophosphamide), the risk of developing life-threatening toxic effects (their severity and duration) increases.

With simultaneous use with zidovudine, the risk of developing neutropenia increases.

Features of the application.

Treatment with laferomax should be carried out under the supervision of a physician.

When treating with the preparation, the use of alcohol should be excluded.

Before prescribing the preparation for a long time, it is recommended to study the function of the thyroid gland. The preparation should be started on the condition that the level of thyroid-stimulating hormone (TSH) is within the normal range. If any changes in the level of thyroid-stimulating hormone are found, appropriate treatment should be carried out and therapy with Laferomax should be started only when the content of thyroid-stimulating hormone can be maintained at a normal level. In the course of treatment, it is advisable to control the level of thyroid-stimulating hormone.

After the termination of therapy, the function of the thyroid gland, impaired as a result of the administration of the preparation, is not restored.

Before starting and regularly during treatment, all patients are advised to carry out a detailed analysis of peripheral blood with a mandatory qualitative and quantitative study of blood parameters, as well as a biochemical blood test, including determination of the content of electrolytes, calcium, liver enzymes and creatinine.

With multiple myeloma, periodic monitoring of renal function is necessary.

In all patients receiving the preparation, it is recommended to carefully monitor the serum albumin level and prothrombin time.

With caution, prescribe the preparation in the presence of a history of diseases such as diabetes mellitus with episodes of ketoacidosis and chronic obstructive pulmonary disease, with blood clotting disorders (including pulmonary artery thrombophlebitis), with severe myelosuppression.

When treating with the preparation, it is necessary to ensure adequate hydration of the body; in case of manifestations of fever, other causes of its occurrence should be excluded.

It is recommended to use the preparation against the background of antihistamine and antipyretic therapy.

If an immediate hypersensitivity reaction develops (urticaria, angioedema, bronchospasm, anaphylaxis), the preparation should be discontinued immediately and appropriate measures should be taken.

The development of severe and moderate severity of side effects requires dose adjustment, and in some cases, discontinuation of preparation treatment.

Discontinue use of the preparation in cases of: prolongation of blood coagulation time (in patients with chronic hepatitis), manifestations of pulmonary syndrome and X-ray detection of infiltration or impaired lung function, appearance or increase in visual impairment, impaired thyroid function (deviation from the normal level of TSH), decrease in the level serum albumin and a decrease in prothrombin time.

After the expiration date, the use of the preparation is unacceptable. The preparation is not subject to repeated quality control and shelf life extension.

Application during pregnancy or lactation.

There are no data on the use of the preparation during pregnancy and lactation.

The ability to influence the reaction rate when driving vehicles or other mechanisms.

Some adverse effects from the central nervous system caused by the use of the preparation can affect the ability of patients to drive vehicles and work with potentially dangerous mechanisms.

Method of administration and dosage.

For adults:

• for papillomavirus infection (vulgar warts, genital warts), the preparation is used rectally at 1,000,000 IU 2 times a day with a 12-hour break. The course of treatment is 10 days. Treatment is carried out by monitoring the patient's condition using a cytological, bacteriological study and observing the manifestation of clinical symptoms;
• for urogenital mixed infections that are sexually transmitted, and for bacterial, viral and mixed infections, the preparation is used rectally at 1,000,000 - 3,000,000 IU 2 times a day with a 12-hour break. The course of treatment is 10 days. Treatment is carried out by monitoring the patient's condition using a cytological, bacteriological study and observing the manifestation of clinical symptoms. Treatment is carried out for both sexual partners;
• for precancerous diseases of the cervix, the preparation is used rectally at 1,000,000 IU 2 times a day with a 12-hour break. The course of treatment is 10 days. Further treatment is determined by clinical and laboratory parameters.

Children.

• Not used in pediatric practice.

Overdose.

To date, no cases of overdose with Laferomax have been described. however, as with any preparation overdose, symptomatic therapy with monitoring of the functions of vital organs and careful monitoring of the patient's condition is recommended.

Adverse reactions.

All adverse reactions associated with the use of laferomax are minor or moderate. they usually disappear after the end of treatment.

The rectal route of administration of the preparation is not accompanied by severe adverse reactions, which are usually observed with parenteral administration of interferon preparations. In some cases, in the first days of treatment, flu-like symptoms may occur, which subsequently decrease and disappear. To prevent them, you can use paracetamol preparations in appropriate age-specific dosages.

General violations. With the introduction of Laferomax, possible flu-like symptoms: chills, fever, fatigue, lethargy, as well as headache, pain in muscles, joints, sweating; rarely - vomiting, dizziness, hot flashes. The occurrence of hypersensitivity reactions to the preparation is possible.

Violation of the hematopoietic system: with prolonged use, leukopenia, thrombocytopenia, anemia, nosebleeds are possible.

Violation of the gastrointestinal tract, liver: increased ALT and AST levels, increased ALP levels, loss of appetite. Liver dysfunction.

Endocrine disorders: dysfunction of the thyroid gland.

Disturbance from the central and peripheral nervous system: with prolonged use, dizziness, sleep disturbance, confusion, anxiety and depression, hyperexcitability, drowsiness, ataxia, paresthesia are possible.

Violation of the cardiovascular system: possible arterial hypertension or hypotension; rarely - tachycardia.

Violation of the skin and subcutaneous tissues: allergic reactions, including rash (including herpes), itching, flushing, urticaria, anaphylactic shock.

Respiratory system disorders: cough.

Other: changes at the injection site, visual impairment, impaired renal function, electrolyte imbalance.

Reports of adverse reactions following preparation registration are important. This makes it possible to continuously monitor the benefit-risk ratio of the preparation. Health professionals are requested to report adverse reactions using the national reporting system.

Shelf life.

2 years.

Storage conditions.

Store in original packaging to protect from light exposure at temperatures from 2 to 8 ºС.

Keep out of the reach of children.

Packaging.

3 or 5 suppositories in a contour cell package. 1 contour cell pack with 3 or 5 suppositories or 2 contour cell packs with 5 suppositories in a cardboard box.